Technology Insight

Biomarker development in acute kidney injury - What can we anticipate?

Bruce Molitoris, Vyacheslav Y. Melnikov, Mark D. Okusa, Jonathan Himmelfarb

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Early diagnosis has been the 'Achilles heel' of acute kidney injury (AKI) that has prevented successful implementation of treatment strategies. To date, pharmacological intervention has been largely unsuccessful or equivocal, and morbidity and mortality associated with AKI have remained unacceptably high. Despite their well-known limitations, the most widely used biomarkers for the early diagnosis of AKI are serum creatinine, blood urea nitrogen and urine output. Development of new biomarkers is imperative. A variety of methods have been employed to discover new biomarkers of AKI, including transcriptomics, proteomics, gene arrays, lipidomics and imaging technologies. Clinical trials are underway to establish the validity of the biomarkers discovered using these techniques. This Review summarizes the importance of biomarkers of AKI, from their discovery to clinical practice, from the current perspective and that of what to expect in the future. Great strides forward are being made in breaking down important barriers to the successful prevention and treatment of this devastating disorder.

Original languageEnglish
Pages (from-to)154-165
Number of pages12
JournalNature Clinical Practice Nephrology
Volume4
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Acute Kidney Injury
Biomarkers
Technology
Early Diagnosis
Blood Urea Nitrogen
Proteomics
Creatinine
Clinical Trials
Urine
Pharmacology
Morbidity
Mortality
Serum
Genes

Keywords

  • Acute renal failure
  • Acute tubular necrosis
  • Glomerular filtration rate
  • Prerenal azotemia
  • Renal function

ASJC Scopus subject areas

  • Nephrology

Cite this

Technology Insight : Biomarker development in acute kidney injury - What can we anticipate? / Molitoris, Bruce; Melnikov, Vyacheslav Y.; Okusa, Mark D.; Himmelfarb, Jonathan.

In: Nature Clinical Practice Nephrology, Vol. 4, No. 3, 03.2008, p. 154-165.

Research output: Contribution to journalArticle

Molitoris, Bruce ; Melnikov, Vyacheslav Y. ; Okusa, Mark D. ; Himmelfarb, Jonathan. / Technology Insight : Biomarker development in acute kidney injury - What can we anticipate?. In: Nature Clinical Practice Nephrology. 2008 ; Vol. 4, No. 3. pp. 154-165.
@article{bf156410a25c4b9288c59724209077ed,
title = "Technology Insight: Biomarker development in acute kidney injury - What can we anticipate?",
abstract = "Early diagnosis has been the 'Achilles heel' of acute kidney injury (AKI) that has prevented successful implementation of treatment strategies. To date, pharmacological intervention has been largely unsuccessful or equivocal, and morbidity and mortality associated with AKI have remained unacceptably high. Despite their well-known limitations, the most widely used biomarkers for the early diagnosis of AKI are serum creatinine, blood urea nitrogen and urine output. Development of new biomarkers is imperative. A variety of methods have been employed to discover new biomarkers of AKI, including transcriptomics, proteomics, gene arrays, lipidomics and imaging technologies. Clinical trials are underway to establish the validity of the biomarkers discovered using these techniques. This Review summarizes the importance of biomarkers of AKI, from their discovery to clinical practice, from the current perspective and that of what to expect in the future. Great strides forward are being made in breaking down important barriers to the successful prevention and treatment of this devastating disorder.",
keywords = "Acute renal failure, Acute tubular necrosis, Glomerular filtration rate, Prerenal azotemia, Renal function",
author = "Bruce Molitoris and Melnikov, {Vyacheslav Y.} and Okusa, {Mark D.} and Jonathan Himmelfarb",
year = "2008",
month = "3",
doi = "10.1038/ncpneph0723",
language = "English",
volume = "4",
pages = "154--165",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Technology Insight

T2 - Biomarker development in acute kidney injury - What can we anticipate?

AU - Molitoris, Bruce

AU - Melnikov, Vyacheslav Y.

AU - Okusa, Mark D.

AU - Himmelfarb, Jonathan

PY - 2008/3

Y1 - 2008/3

N2 - Early diagnosis has been the 'Achilles heel' of acute kidney injury (AKI) that has prevented successful implementation of treatment strategies. To date, pharmacological intervention has been largely unsuccessful or equivocal, and morbidity and mortality associated with AKI have remained unacceptably high. Despite their well-known limitations, the most widely used biomarkers for the early diagnosis of AKI are serum creatinine, blood urea nitrogen and urine output. Development of new biomarkers is imperative. A variety of methods have been employed to discover new biomarkers of AKI, including transcriptomics, proteomics, gene arrays, lipidomics and imaging technologies. Clinical trials are underway to establish the validity of the biomarkers discovered using these techniques. This Review summarizes the importance of biomarkers of AKI, from their discovery to clinical practice, from the current perspective and that of what to expect in the future. Great strides forward are being made in breaking down important barriers to the successful prevention and treatment of this devastating disorder.

AB - Early diagnosis has been the 'Achilles heel' of acute kidney injury (AKI) that has prevented successful implementation of treatment strategies. To date, pharmacological intervention has been largely unsuccessful or equivocal, and morbidity and mortality associated with AKI have remained unacceptably high. Despite their well-known limitations, the most widely used biomarkers for the early diagnosis of AKI are serum creatinine, blood urea nitrogen and urine output. Development of new biomarkers is imperative. A variety of methods have been employed to discover new biomarkers of AKI, including transcriptomics, proteomics, gene arrays, lipidomics and imaging technologies. Clinical trials are underway to establish the validity of the biomarkers discovered using these techniques. This Review summarizes the importance of biomarkers of AKI, from their discovery to clinical practice, from the current perspective and that of what to expect in the future. Great strides forward are being made in breaking down important barriers to the successful prevention and treatment of this devastating disorder.

KW - Acute renal failure

KW - Acute tubular necrosis

KW - Glomerular filtration rate

KW - Prerenal azotemia

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=39749087729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749087729&partnerID=8YFLogxK

U2 - 10.1038/ncpneph0723

DO - 10.1038/ncpneph0723

M3 - Article

VL - 4

SP - 154

EP - 165

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 3

ER -